New hope for Hard-to-Treat cancers: ERAS-4001 enters human trials
NCT ID NCT07021898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called ERAS-4001 in people with advanced solid tumors that have certain KRAS mutations. The main goal is to see if the drug is safe and find the best dose, either alone or with other treatments. About 200 adults who have no good standard options left can join.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
-
NEXT Oncology
RECRUITINGIrving, Texas, 75039, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITINGNashville, Tennessee, 32703, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can your own immune cells fight advanced cancer?
- Can a radioactive antibody light up hidden cancers on PET scans?
- Blood test may let cancer patients take safe breaks from immunotherapy
- Off-the-Shelf cell therapy takes on Hard-to-Treat cancers
- New drug duo aims to reboot immune attack on Hard-to-Treat cancers